HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
27 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MUTYH
mutY DNA glycosylase
Chromosome 1 Β· 1p34.1
NCBI Gene: 4595Ensembl: ENSG00000132781.22HGNC: HGNC:7527UniProt: A0AAQ5BGW7
319PubMed Papers
22Diseases
0Drugs
416Pathogenic Variants
FUNCTIONAL ROLE
DNA RepairTumor Suppressor
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
MutSalpha complex bindingMutLbeta complex bindingMutSbeta complex bindingpurine-specific mismatch base pair DNA N-glycosylase activityfamilial adenomatous polyposis 2Familial adenomatous polyposisgastric cancercolorectal cancer
✦AI Summary

MUTYH (mutY DNA glycosylase) is a base excision repair enzyme that removes inappropriately paired adenine bases opposite 8-oxoguanine lesions, preventing G:C to T:A transversions caused by oxidative DNA damage 1. The protein possesses both adenine and 2-OH-A DNA glycosylase activities and functions in the nucleoplasm and mitochondria as part of mismatch repair pathways 1. Biallelic MUTYH mutations cause MUTYH-associated polyposis (MAP), an autosomal recessive syndrome characterized by multiple colorectal adenomas and very high colorectal cancer risk, phenotypically similar to familial adenomatous polyposis 2. Monoallelic mutations confer increased colorectal cancer risk even without biallelic inheritance 3. Loss of functional MUTYH protein results in accumulation of G:T mismatches and characteristic mutational signatures in tumors 4. Beyond colorectal disease, germline MUTYH mutations increase risk for duodenal adenomas, gastric cancer, and pancreatic neuroendocrine tumors 5. Functional studies show missense variants exhibit variable complementation activity, with some variants severely impairing glycosylase activity while others retain near-normal function 6. MAP patients require specialized genetic counseling and lifelong surveillance protocols.

Sources cited
1
MUTYH encodes a base excision repair protein preventing G:C to T:A transversions; biallelic mutations cause familial colorectal cancer; characterization of mutant variants' glycosylase and DNA binding activities
PMID: 18534194
2
MAP is autosomal recessive disorder with adenomatous polyps and high colorectal cancer risk; phenotypically similar to APC-mediated FAP; increased risk for duodenal adenomas and extraintestinal tumors
PMID: 19414147
3
Biallelic MUTYH mutations found in 2.2% of colorectal cancer patients; monoallelic MUTYH mutations in 3.6% with moderate cancer risk; mutations identified in unselected CRC populations
PMID: 28135145
4
MUTYH inactivation causes G:C > T:A base excision repair deficiency signature in pancreatic neuroendocrine tumors; germline MUTYH mutations in sporadic PanNETs
PMID: 28199314
5
Updated European guidelines for MAP management; MUTYH-associated polyposis recognized as distinct adenomatous polyposis syndrome with gastric cancer and other extracolonic manifestations
PMID: 38722804
6
Functional complementation assay showing MUTYH variants exhibit variable activity from complete loss to near-normal function; loss of MUTYH function causes G:T mismatch accumulation
PMID: 25820570
7
MAP is only polyposis syndrome with autosomal recessive inheritance; biallelic mutations required for disease; monoallelic carriers have increased colorectal cancer risk
PMID: 31094179
8
MUTYH identified as germline cancer susceptibility gene variant in patients with Cowden/BRRS syndromes without PTEN mutations
PMID: 29684080
Disease Associationsβ“˜22
familial adenomatous polyposis 2Open Targets
0.85Strong
Familial adenomatous polyposisOpen Targets
0.77Strong
gastric cancerOpen Targets
0.70Moderate
colorectal cancerOpen Targets
0.62Moderate
colon carcinomaOpen Targets
0.61Moderate
mutyh-associated polyposisOpen Targets
0.58Moderate
hereditary neoplastic syndromeOpen Targets
0.58Moderate
Inherited cancer-predisposing syndromeOpen Targets
0.58Moderate
breast carcinomaOpen Targets
0.57Moderate
colorectal adenocarcinomaOpen Targets
0.55Moderate
PilomatrixomaOpen Targets
0.51Moderate
stomach neoplasmOpen Targets
0.51Moderate
familial colorectal cancerOpen Targets
0.50Moderate
colonic neoplasmOpen Targets
0.50Moderate
familial colorectal cancer type XOpen Targets
0.49Moderate
cancerOpen Targets
0.48Moderate
malignant colon neoplasmOpen Targets
0.46Moderate
diffuse midline glioma, H3 K27-alteredOpen Targets
0.44Moderate
hereditary breast carcinomaOpen Targets
0.43Moderate
Hereditary breast cancerOpen Targets
0.43Moderate
Familial adenomatous polyposis 2UniProt
Gastric cancerUniProt
Pathogenic Variants416
NM_001048174.2(MUTYH):c.1063del (p.Ala357fs)Pathogenic
not specified|Carcinoma of colon|Hereditary cancer-predisposing syndrome|Familial adenomatous polyposis 2|not provided|Familial colorectal cancer|MUTYH-related disorder|Familial adenomatous polyposis 2;Gastric cancer|Colorectal cancer
β˜…β˜…β˜†β˜†2026β†’ Residue 357
NM_001048174.2(MUTYH):c.386C>T (p.Pro129Leu)Pathogenic
Hereditary cancer-predisposing syndrome|Familial adenomatous polyposis 2|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 129
NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp)Pathogenic
Familial adenomatous polyposis 2|not provided|Endometrial cancer|not specified|Carcinoma of colon|Hereditary cancer-predisposing syndrome|Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas|Small intestine carcinoid|Neoplasm of stomach;Familial adenomatous polyposis 2;Pilomatrixoma|Neoplasm of stomach;Familial adenomatous polyposis 2|Ovarian carcinoma|Breast carcinoma|Colon cancer|Familial colorectal cancer|MUTYH-related disorder|Diffuse midline glioma, H3 K27-altered|Gastric cancer;Familial adenomatous polyposis 2|Inherited polyposis and early onset colorectal cancer - germline testing|Pilocytic astrocytoma|Ependymoma|Pleomorphic xanthoastrocytoma BRAF mutant|Infant-type hemispheric glioma
β˜…β˜…β˜†β˜†2026β†’ Residue 368
NM_001048174.2(MUTYH):c.383G>A (p.Trp128Ter)Pathogenic
Hereditary cancer-predisposing syndrome|not provided|Familial adenomatous polyposis 2|Carcinoma of colon|Familial adenomatous polyposis 2;Gastric cancer|Gastric cancer
β˜…β˜…β˜†β˜†2026β†’ Residue 128
NM_001048174.2(MUTYH):c.452A>G (p.Tyr151Cys)Pathogenic
Familial adenomatous polyposis 2|not provided|Endometrial carcinoma|Hereditary cancer-predisposing syndrome|not specified|Carcinoma of colon|Gastric cancer|Gastric cancer;Familial adenomatous polyposis 2|MUTYH-related disorder|Dysembryoplastic neuroepithelial tumor|Inherited polyposis and early onset colorectal cancer - germline testing|Colorectal cancer|Pilocytic astrocytoma|Medulloblastoma
β˜…β˜…β˜†β˜†2026β†’ Residue 151
NM_001048174.2(MUTYH):c.1103-2A>GPathogenic
Hereditary cancer-predisposing syndrome|Carcinoma of colon|Familial adenomatous polyposis 2|not provided|Familial adenomatous polyposis 2;Gastric cancer
β˜…β˜…β˜†β˜†2026
NM_001048174.2(MUTYH):c.652G>T (p.Val218Phe)Pathogenic
Familial adenomatous polyposis 2|Hereditary cancer-predisposing syndrome|not provided|Pilomatrixoma|Familial adenomatous polyposis 2;Gastric cancer
β˜…β˜…β˜†β˜†2026β†’ Residue 218
NM_001048174.2(MUTYH):c.1350GGA[1] (p.Glu452del)Pathogenic
Hereditary cancer-predisposing syndrome|not specified|Familial adenomatous polyposis 2|not provided|Breast carcinoma|Colorectal polyposis|Gastric cancer;Familial adenomatous polyposis 2|Hereditary breast ovarian cancer syndrome|Medulloblastoma SHH activated and TP53 wild-type
β˜…β˜…β˜†β˜†2026β†’ Residue 452
NM_001048174.2(MUTYH):c.649C>T (p.Arg217Cys)Pathogenic
Familial adenomatous polyposis 2|Hereditary cancer-predisposing syndrome|not provided|Familial colorectal cancer|Familial adenomatous polyposis 2;Gastric cancer|Gastric cancer
β˜…β˜…β˜†β˜†2026β†’ Residue 217
NM_001048174.2(MUTYH):c.460C>T (p.Arg154Cys)Pathogenic
Hereditary cancer-predisposing syndrome|Familial adenomatous polyposis 2|not provided|Pilomatrixoma|Ovarian cancer
β˜…β˜…β˜†β˜†2026β†’ Residue 154
NM_001048174.2(MUTYH):c.248T>C (p.Leu83Pro)Pathogenic
Familial adenomatous polyposis 2|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜†β˜†2026β†’ Residue 83
NM_001048174.2(MUTYH):c.1130C>T (p.Pro377Leu)Pathogenic
Carcinoma of colon|Hereditary cancer-predisposing syndrome|Familial adenomatous polyposis 2|not provided|B lymphoblastic leukemia lymphoma, no ICD-O subtype|Familial adenomatous polyposis 2;Gastric cancer
β˜…β˜…β˜†β˜†2026β†’ Residue 377
NM_001048174.2(MUTYH):c.650G>A (p.Arg217His)Pathogenic
Hereditary cancer-predisposing syndrome|Familial adenomatous polyposis 2|not provided|Familial adenomatous polyposis 2;Neoplasm of stomach;Pilomatrixoma|Breast carcinoma|Carcinoma of colon|Diffuse midline glioma, H3 K27-altered|MUTYH-related disorder|Familial adenomatous polyposis 2;Gastric cancer
β˜…β˜…β˜†β˜†2026β†’ Residue 217
NM_001048174.2(MUTYH):c.1354G>T (p.Glu452Ter)Pathogenic
Familial adenomatous polyposis 2|Hereditary cancer-predisposing syndrome|not provided|Gastric cancer;Familial adenomatous polyposis 2|Carcinoma of colon|MUTYH-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 452
NM_001048174.2(MUTYH):c.228C>A (p.Tyr76Ter)Pathogenic
Familial adenomatous polyposis 2|Hereditary cancer-predisposing syndrome|Familial colorectal cancer|not provided|Carcinoma of colon|Gastric cancer;Familial adenomatous polyposis 2|Ovarian cancer|Medulloblastoma SHH activated and TP53 wild-type
β˜…β˜…β˜†β˜†2026β†’ Residue 76
NM_001048174.2(MUTYH):c.773G>A (p.Gly258Glu)Pathogenic
not provided|Familial adenomatous polyposis 2|Hereditary cancer-predisposing syndrome|Gastric cancer|Familial adenomatous polyposis 2;Gastric cancer
β˜…β˜…β˜†β˜†2026β†’ Residue 258
NM_001048174.2(MUTYH):c.629A>G (p.Asn210Ser)Pathogenic
not provided|Familial adenomatous polyposis 2|Hereditary cancer-predisposing syndrome|Carcinoma of colon
β˜…β˜…β˜†β˜†2026β†’ Residue 210
NM_001048174.2(MUTYH):c.1143_1144dup (p.Glu382fs)Pathogenic
Hereditary cancer-predisposing syndrome|Carcinoma of colon|Familial adenomatous polyposis 2|not provided|MUTYH-related disorder|Gastric cancer;Familial adenomatous polyposis 2
β˜…β˜…β˜†β˜†2026β†’ Residue 382
NM_001048174.2(MUTYH):c.1393G>T (p.Val465Phe)Pathogenic
Familial adenomatous polyposis 2|Hereditary cancer-predisposing syndrome|not provided|Familial adenomatous polyposis 2;Gastric cancer|MUTYH-related disorder|Clear cell carcinoma of kidney
β˜…β˜…β˜†β˜†2026β†’ Residue 465
NM_001048174.2(MUTYH):c.715C>T (p.Gln239Ter)Pathogenic
Hereditary cancer-predisposing syndrome|Familial adenomatous polyposis 2|not provided|Gastric cancer
β˜…β˜…β˜†β˜†2026β†’ Residue 239
View on ClinVar β†—
Related Genes
XRCC1Protein interaction100%MLH3Protein interaction100%PMS1Protein interaction100%MYH2Protein interaction99%OGG1Protein interaction99%APEX1Protein interaction98%
Tissue Expression6 tissues
Ovary
100%
Liver
67%
Bone Marrow
63%
Lung
56%
Brain
38%
Heart
35%
Gene Interaction Network
Click a node to explore
MUTYHXRCC1MLH3PMS1MYH2OGG1APEX1
PROTEIN STRUCTURE
Preparing viewer…
PDB8FAY Β· 1.91 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.02LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.83 [0.68–1.02]
RankingsWhere MUTYH stands among ~20K protein-coding genes
  • #1,052of 20,598
    Most Researched319 Β· top 10%
  • #132of 5,498
    Most Pathogenic Variants416 Β· top 5%
  • #10,037of 17,882
    Most Constrained (LOEUF)1.02
Genes detectedMUTYH
Sources retrieved27 papers
Response timeβ€”
πŸ“„ Sources
27β–Ό
1
Whole-genome landscape of pancreatic neuroendocrine tumours.
PMID: 28199314
Nature Β· 2017
1.00
2
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer.
PMID: 28135145
J Clin Oncol Β· 2017
0.90
3
Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision.
PMID: 38722804
Br J Surg Β· 2024
0.80
4
Characterization of mutant MUTYH proteins associated with familial colorectal cancer.
PMID: 18534194
Gastroenterology Β· 2008
0.70
5
Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
PMID: 30613976
Int J Cancer Β· 2019
0.68